

Paulo Gustavo kotze

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3378967/publications.pdf>

Version: 2024-02-01

188
papers

4,634
citations

201385

27
h-index

123241

61
g-index

193
all docs

193
docs citations

193
times ranked

4319
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Laparoscopic Ileal Resection for Localized Ileocecal Crohn's Disease: Hard Sell or a Revolutionary New Norm?. <i>Inflammatory Intestinal Diseases</i> , 2022, 7, 13-20.	0.8	14
2	Perception and clinical decisions from inflammatory bowel diseases specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB). <i>Gastroenterology & Hepatology</i> , 2022, 45, 499-506.	0.2	0
3	Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 69-95.	3.7	41
4	P563 Association between smoking status and the efficacy and safety of tofacitinib in patients with Ulcerative Colitis: Data from the tofacitinib clinical programme. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i506-i507.	0.6	1
5	Twenty-first Century Trends in the Global Epidemiology of Pediatric-Onset Inflammatory Bowel Disease: Systematic Review. <i>Gastroenterology</i> , 2022, 162, 1147-1159.e4.	0.6	192
6	The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases. <i>Clinics in Colon and Rectal Surgery</i> , 2022, 35, 003-004.	0.5	2
7	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 254-261.	3.7	18
8	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2619-2627.e1.	2.4	9
9	New insights on the surgical management of ulcerative colitis in the 21st century. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 679-688.	3.7	7
10	Patient-reported Outcome Measures in Perianal Fistulizing Crohn's Disease. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, 143-155.	0.4	0
11	Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB). <i>BMC Gastroenterology</i> , 2022, 22, .	0.8	1
12	Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study. <i>The Lancet Regional Health Americas</i> , 2022, 13, 100298.	1.5	9
13	Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1366-1376.e2.	2.4	55
14	Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic. <i>Gastroenterology</i> , 2021, 160, 472-473.	0.6	2
15	Surgery for Inflammatory Bowel Disease Has Unclear Impact on Female Fertility: A Cochrane Collaboration Systematic Review. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 115-124.	0.1	6
16	Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110057.	1.4	20
17	Importance of Nutrition and Hypoalbuminaemia in Postoperative Morbidity in Crohn's Disease: Thinking Outside of the Box on Biologics as Single Risk Factors. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1401-1402.	0.6	2
18	Exploring the Relationship between Biologics and Postoperative Surgical Morbidity in Ulcerative Colitis: A Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 710.	1.0	4

#	ARTICLE	IF	CITATIONS
19	CORRELATION BETWEEN TROUGH LEVELS OF INFLIXIMAB AND POSTOPERATIVE ENDOSCOPIC RECURRENT IN CROHN'S DISEASE PATIENTS SUBMITTED TO ILEOCOLONIC RESECTIONS: A SYSTEMATIC REVIEW. <i>Arquivos Brasileiros de Gastroenterologia</i> , 2021, 58, 107-113.	0.3	4
20	Practical insights into stomas in inflammatory bowel disease: what every healthcare provider needs to know. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 320-327.	1.0	4
21	Training on Minimally Invasive Colorectal Surgery during Surgical Residency: Integrating Surgical Education and Advanced Techniques. <i>Clinics in Colon and Rectal Surgery</i> , 2021, 34, 194-200.	0.5	4
22	Preoperative Anti-TNF Agents and Morbidity After Ileocolonic Resections in Crohn's Disease: Are Biologics the Only Ones to Blame?. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1352-1353.	0.9	1
23	Training for Minimally Invasive Surgery for IBD: A Current Need. <i>Clinics in Colon and Rectal Surgery</i> , 2021, 34, 172-180.	0.5	5
24	Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey. <i>World Journal of Gastroenterology</i> , 2021, 27, 1226-1239.	1.4	1
25	Advances in Inflammatory Bowel Diseases 2020 Virtual: Key Take-Home Points. <i>Diseases of the Colon and Rectum</i> , 2021, 64, 774-776.	0.7	0
26	Adjunctive Hyperbaric Oxygen Therapy in Refractory Crohn's Disease: An Observational Study. <i>Gastroenterology Research and Practice</i> , 2021, 2021, 1-8.	0.7	7
27	International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. <i>United European Gastroenterology Journal</i> , 2021, 9, 451-460.	1.6	31
28	DOP41 Temporal Trends in the epidemiology of Inflammatory Bowel Diseases in the public healthcare system in Brazil: A large population-based study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S079-S080.	0.6	3
29	DOP61 Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S096-S097.	0.6	0
30	P644 Hospitalization and abdominal surgery rates in CD according to drug-dispensing: a temporal trend analysis from the Brazilian public healthcare national system. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S576-S577.	0.6	1
31	P591 Anti-TNF therapy for Ulcerative Colitis in Brazil: a comparative real-world national multicentric study from the Brazilian Study Group of IBD (GEDIIB). <i>Journal of Crohn's and Colitis</i> , 2021, 15, S540-S541.	0.6	0
32	Perioperative Nutritional Optimization in Inflammatory Bowel Diseases: When and How?. <i>Journal of Coloproctology</i> , 2021, 41, 295-300.	0.1	1
33	The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 429-440.	1.9	15
34	Thiopurines: Use them or lose them? International survey on current and future use of thiopurines in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2021, 53, 1571-1579.	0.4	3
35	Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 482-497.	3.7	28
36	COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3033-3040.	1.4	10

#	ARTICLE	IF	CITATIONS
37	Patients'™ perceptions of surgery for inflammatory bowel disease. <i>Colorectal Disease</i> , 2021, 23, 2690-2698.	0.7	5
38	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102849.	2.5	12
39	Correlation of serum levels of anti-tumor necrosis factor agents with perianal fistula healing in Crohn's™ disease: a narrative review. <i>Intestinal Research</i> , 2021, 19, 255-264.	1.0	6
40	International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 857-873.	8.2	56
41	Inflammatory bowel disease epidemiology data from a prospective registry in Córdoba, Argentina: Raising the bar for future studies in Latin America. <i>Digestive and Liver Disease</i> , 2021, 53, 1212-1213.	0.4	3
42	Endoscopic evaluation after surgery in inflammatory bowel disease – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 691-692.	3.7	0
43	Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 826-849.	3.7	69
44	PREVALENCE OF SELF-MEDICATION FOR DYSPEPTIC SYMPTOMS IN PRIMARY CARE: A BRAZILIAN SURVEY. <i>Arquivos De Gastroenterologia</i> , 2021, 58, 364-369.	0.3	2
45	Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient. <i>Journal of Clinical Medicine</i> , 2021, 10, 5642.	1.0	4
46	Sucralfate enemas reduce the oxidative tissue damage and preserves the contents of E-cadherin and β -catenin in colonic mucosa without fecal stream. <i>Acta Cirurgica Brasileira</i> , 2021, 36, e361007.	0.3	2
47	MANAGEMENT OF ILEOCECAL CROHN'S™ DISEASE DURING SURGICAL TREATMENT FOR ACUTE APPENDICITIS: A SYSTEMATIC REVIEW. <i>Arquivos De Gastroenterologia</i> , 2021, 58, 560-565.	0.3	4
48	Perioperative Dietary Therapy in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 431-444.	0.6	46
49	Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 304-312.	2.4	129
50	Microscopic Inflammation at Ileocaecal Resection Margins in Crohn's™ Disease: Prevent Recurrence or Treat Residual Disease?. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 872-873.	0.6	2
51	Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis?. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 189-190.	1.9	2
52	Review of the epidemiology and burden of ulcerative colitis in Latin America. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093173.	1.4	27
53	Perioperative management of ileocecal Crohn's™ disease in the current era. <i>Expert Review of Gastroenterology and Hepatology</i> , 2020, 14, 843-855.	1.4	8
54	Biologics and surgical outcomes in Crohn's™ disease: is there a direct relationship?. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093173.	1.4	14

#	ARTICLE	IF	CITATIONS
55	Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 702-710.	8.2	57
56	Management of Isolated Anal Strictures in Crohn's Disease. Diseases of the Colon and Rectum, 2020, 63, 1639-1647.	0.7	3
57	Reduction of surgical rates in inflammatory bowel diseases biologic era: Similarities between Spain and Latin America. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1453-1453.	1.4	1
58	Fistulizing Crohn's disease. Current Problems in Surgery, 2020, 57, 100808.	0.6	14
59	Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis—two cases in real world clinical practice. Alimentary Pharmacology and Therapeutics, 2020, 51, 1208-1209.	1.9	3
60	Crohn's disease. Nature Reviews Disease Primers, 2020, 6, 22.	18.1	420
61	Optimal strategies to prevent recrudescence Crohn's disease after resection. Seminars in Colon and Rectal Surgery, 2020, 31, 100746.	0.2	0
62	International Organization for the Study of IBD Recommendations for Surgery in Patients With IBD During the Coronavirus Disease 2019 Pandemic. Diseases of the Colon and Rectum, 2020, 63, 870-873.	0.7	13
63	Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. The Lancet Gastroenterology and Hepatology, 2020, 5, 393-405.	3.7	78
64	Up-to-date surgery for ulcerative colitis in the era of biologics. Expert Opinion on Biological Therapy, 2020, 20, 391-398.	1.4	8
65	Research in inflammatory bowel disease in Brazil: a step forward towards patient care. Arquivos De Gastroenterologia, 2020, 57, 225-226.	0.3	2
66	Robotic Surgery in Inflammatory Bowel Disease. Current Drug Targets, 2020, 22, 112-116.	1.0	11
67	INDUCTION THERAPEUTIC DRUG MONITORING REGIMEN WITH INFLIXIMAB: A SIMPLIFIED EVIDENCE-BASED ALGORITHM FOR INFLAMMATORY BOWEL DISEASE. Arquivos De Gastroenterologia, 2020, 57, 507-510.	0.3	2
68	Education levels and survival in colorectal cancer: is there really an obvious association?. Intestinal Research, 2020, 18, 247-248.	1.0	2
69	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. Journal of Crohn's and Colitis, 2019, 13, 144-164K.	0.6	958
70	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. Journal of Crohn's and Colitis, 2019, 13, 273-284.	0.6	250
71	Impact of Preoperative Nutritional Status on the Incidence Rate of Surgical Complications in Patients With Inflammatory Bowel Disease With Vs Without Preoperative Biologic Therapy: A Case-Control Study. Clinical and Translational Gastroenterology, 2019, 10, e00050.	1.3	25
72	Mesenchymal Stem Cells for Perianal Crohn's Disease. Cells, 2019, 8, 764.	1.8	73

#	ARTICLE	IF	CITATIONS
73	P388 Analysis of the impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis programme. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S301-S302.	0.6	1
74	SURGICAL STRATEGIES IN MULTIDISCIPLINARY MANAGEMENT OF CROHN'S DISEASE. <i>Revista Médica Clínica Las Condes</i> , 2019, 30, 349-356.	0.2	0
75	Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 969-970.	1.9	1
76	Biological Treatment and the Potential Risk of Adverse Postoperative Outcome in Patients With Inflammatory Bowel Disease: An Open-Source Expert Panel Review of the Current Literature and Future Perspectives. <i>Crohn's & Colitis</i> 360, 2019, 1, .	0.5	3
77	Medico-surgical Management: A Solid Therapeutic Pillar for Improved Patients' Outcomes in Inflammatory Bowel Diseases. <i>Current Drug Targets</i> , 2019, 20, 1315-1316.	1.0	0
78	Reduction in surgical stoma rates in Crohn's disease: a population-based time trend analysis. <i>Colorectal Disease</i> , 2019, 21, 1279-1287.	0.7	12
79	Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?. <i>Current Medicinal Chemistry</i> , 2019, 26, 246-247.	1.2	0
80	Ileal pouch-anal anastomosis with fluorescence angiography: a case-matched study. <i>Colorectal Disease</i> , 2019, 21, 827-832.	0.7	23
81	Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 287-295.	3.7	44
82	Concomitant Use of Aminosalicylates Is Not Associated With Improved Outcomes in Patients With Ulcerative Colitis Escalated to Vedolizumab. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2374-2376.e2.	2.4	15
83	The impact of surgical therapies for inflammatory bowel disease on female fertility. <i>The Cochrane Library</i> , 2019, 7, CD012711.	1.5	22
84	The globalization of inflammatory bowel disease. <i>Current Opinion in Gastroenterology</i> , 2019, 35, 259-264.	1.0	40
85	Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 215-237.	0.5	61
86	Darvadstrocel for the treatment of patients with perianal fistulas in Crohn's disease. <i>Drugs of Today</i> , 2019, 55, 95.	0.7	14
87	BIOLOGICAL THERAPY PENETRATION FOR INFLAMMATORY BOWEL DISEASE IN LATIN AMERICA: CURRENT STATUS AND FUTURE CHALLENGES. <i>Arquivos De Gastroenterologia</i> , 2019, 56, 318-322.	0.3	12
88	Effects of anti-TNF- α in experimental diversion colitis. <i>Acta Cirurgica Brasileira</i> , 2019, 34, e201901004.	0.3	9
89	Cell-based Therapy for Perianal Fistulising Crohn's Disease. <i>Current Pharmaceutical Design</i> , 2019, 25, 41-46.	0.9	5
90	Prevention of Postoperative Recurrence in CD: Tailoring Treatment to Patient Profile. <i>Current Drug Targets</i> , 2019, 20, 1327-1338.	1.0	3

#	ARTICLE	IF	CITATIONS
91	Anti-TNF and Postoperative Complications in Abdominal Crohn's Disease Surgery. <i>Current Drug Targets</i> , 2019, 20, 1339-1348.	1.0	7
92	Pre-operative Exposure to Ustekinumab: A Risk Factor for Postoperative Complications in Crohn's Disease (CD)?. <i>Current Drug Targets</i> , 2019, 20, 1369-1372.	1.0	5
93	Hypoalbuminemia as a risk factor for thromboembolic events in inflammatory bowel disease inpatients. <i>Intestinal Research</i> , 2019, 17, 63-69.	1.0	9
94	Serum levels of infliximab in Brazilian patients with Crohn's disease: what are the reasons for differences from previous studies?. <i>Clinics</i> , 2019, 74, e1424.	0.6	1
95	VEDOLIZUMAB IN THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES: A BRAZILIAN OBSERVATIONAL MULTICENTRIC STUDY. <i>Arquivos De Gastroenterologia</i> , 2019, 56, 312-317.	0.3	7
96	Fluorescence angiography during transanal trans-œstomal proctectomy and ileal pouch anal anastomosis – a video vignette. <i>Colorectal Disease</i> , 2018, 20, 262-263.	0.7	19
97	Modern management of perianal fistulas in Crohn's disease: future directions. <i>Gut</i> , 2018, 67, 1181-1194.	6.1	114
98	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Disease – an International, Cross-disciplinary Consensus. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 408-418.	0.6	102
99	Adalimumab and postoperative complications of elective intestinal resections in Crohn's disease: a propensity score case-matched study. <i>Colorectal Disease</i> , 2018, 20, 211-218.	0.7	18
100	Staging surgery for ulcerative colitis: more than meets the eye. <i>International Journal of Colorectal Disease</i> , 2018, 33, 109-110.	1.0	0
101	Glucose Metabolism Parameters and Post-Prandial GLP-1 and GLP-2 Release Largely Vary in Several Distinct Situations: a Controlled Comparison Among Individuals with Crohn's Disease and Individuals with Obesity Before and After Bariatric Surgery. <i>Obesity Surgery</i> , 2018, 28, 378-388.	1.1	12
102	P436 Ileal pouch-anal anastomosis with fluorescence angiography: Initial experience and potential application. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S325-S325.	0.6	0
103	Letter: can a specific surgical approach reduce post-operative recurrence in Crohn's disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1030-1031.	1.9	0
104	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 115-123.	0.1	34
105	Editorial: biologic therapies for primary sclerosing cholangitis – more disappointment than promise?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 576-577.	1.9	1
106	Evolving Role of IBD Surgery. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 1005-1007.	0.6	50
107	Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878361.	1.4	11
108	SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT. <i>Arquivos De Gastroenterologia</i> , 2018, 55, 192-197.	0.3	6

#	ARTICLE	IF	CITATIONS
109	Real-world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 626-637.	1.9	43
110	Long Time from Diagnosis to Surgery May Increase Postoperative Complication Rates in Elective CD Intestinal Resections: An Observational Study. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-6.	0.7	13
111	VISCERAL FAT IS INCREASED IN INDIVIDUALS WITH CROHN'S DISEASE: A COMPARATIVE ANALYSIS WITH HEALTHY CONTROLS. <i>Arquivos De Gastroenterologia</i> , 2018, 55, 142-147.	0.3	19
112	TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES. <i>Arquivos De Gastroenterologia</i> , 2018, 55, 198-200.	0.3	4
113	Fistula-associated anal carcinoma in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 917-925.	1.4	20
114	Clinical utility of ustekinumab in Crohn's disease. <i>Journal of Inflammation Research</i> , 2018, Volume 11, 35-47.	1.6	32
115	The old versus the new: which do you keep in postoperative Crohn's disease?. <i>Intestinal Research</i> , 2018, 16, 319.	1.0	2
116	Surgery in ulcerative colitis: When? How?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 71-78.	1.0	56
117	The impact of biologics in surgical outcomes in ulcerative colitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 32-33, 79-87.	1.0	16
118	Postoperative Approach for Crohn's Disease: The Right Therapy to the Right Patient. <i>Current Drug Targets</i> , 2018, 19, 729-739.	1.0	7
119	Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy Access to Rapid Treatment (iSTART) approach. <i>Intestinal Research</i> , 2018, 16, 522-528.	1.0	17
120	Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease. <i>Intestinal Research</i> , 2018, 16, 62.	1.0	7
121	Can Surgery for Inflammatory Bowel Disease be Personalized?. <i>Current Drug Targets</i> , 2018, 19, 798-804.	1.0	0
122	Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. <i>Revista De Gastroenterología De México (English Edition)</i> , 2017, 82, 46-84.	0.1	7
123	Postoperative mortality in inflammatory bowel disease patients. <i>Journal of Coloproctology</i> , 2017, 37, 116-122.	0.1	3
124	Situaciones especiales en la enfermedad inflamatoria intestinal: primer consenso latinoamericano de la Pan American Crohn's and Colitis Organisation (PANCCO) (Segunda parte). <i>Revista De Gastroenterología De México</i> , 2017, 82, 134-155.	0.4	4
125	Factors affecting the incidence of early endoscopic recurrence after ileocolonic resection for Crohn's disease: a multicentre observational study. <i>Colorectal Disease</i> , 2017, 19, O39-O45.	0.7	26
126	Tumor Necrosis Factor Alpha Inhibitors Did Not Influence Postoperative Morbidity After Elective Surgical Resections in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 456-464.	1.1	50

#	ARTICLE	IF	CITATIONS
127	Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista De Gastroenterología De México, 2017, 82, 46-84.	0.4	22
128	Postoperative complication rates between Crohn's disease and Colorectal cancer patients after ileocolic resections: a comparative study. Journal of Coloproctology, 2017, 37, 290-294.	0.1	1
129	Double single-port transanal pouch surgery: a novel technique for rectal excision and ileo-anal pouch anastomosis for ulcerative colitis. Journal of Coloproctology, 2017, 37, 328-331.	0.1	2
130	ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY. Arquivos De Gastroenterologia, 2017, 54, 321-327.	0.3	7
131	Changes in serum levels of lipopolysaccharides and CD26 in patients with Crohn's disease. Intestinal Research, 2017, 15, 352.	1.0	28
132	SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFlixIMAB AND ADALIMUMAB. Arquivos De Gastroenterologia, 2017, 54, 328-332.	0.3	9
133	Obesity and Crohn's disease: what comes first, the egg or the chicken?. Arquivos De Gastroenterologia, 2017, 54, 268-268.	0.3	3
134	Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls. Intestinal Research, 2017, 15, 160.	1.0	11
135	Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico. Journal of Medical Economics, 2016, 19, 1187-1199.	1.0	7
136	Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: Does Smoke Always Mean Fire?. Journal of Crohn's and Colitis, 2016, 11, jcw205.	0.6	6
137	Anal Squamous Cell Carcinoma: An Infrequent Challenge in the Management of Ulcerative Colitis Under Combination Therapy. Journal of Crohn's and Colitis, 2016, 10, 626-627.	0.6	2
138	Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. United European Gastroenterology Journal, 2016, 4, 784-793.	1.6	68
139	Anal Fistula Plug for Perianal Fistulising Crohn's Disease: an Important Trial for Inflammatory Bowel Disease Surgeons. Journal of Crohn's and Colitis, 2016, 10, 125-126.	0.6	0
140	Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease—the Unmet Needs. Journal of Crohn's and Colitis, 2016, 10, 758-765.	0.6	49
141	ANVISA APPROVES THE FIRST BIOSIMILAR MONOCLONAL ANTIBODY BASED ON COMPARABILITY IN BRAZIL. Arquivos De Gastroenterologia, 2016, 53, 60-61.	0.3	3
142	THE APPROVAL OF VEDOLIZUMAB FOR THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASES IN BRAZIL: the beginning of a new biological era. Arquivos De Gastroenterologia, 2016, 53, 3-4.	0.3	1
143	Adalimumab for Perianal Fistulizing Crohn's Disease. Journal of Clinical Gastroenterology, 2015, 49, 174-175.	1.1	2
144	FECAL CALPROTECTIN: levels for the ethiological diagnosis in Brazilian patients with gastrointestinal symptoms. Arquivos De Gastroenterologia, 2015, 52, 50-54.	0.3	17

#	ARTICLE	IF	CITATIONS
145	BIOSIMILARS IN INFLAMMATORY BOWEL DISEASES: an important moment for Brazilian gastroenterologists. <i>Arquivos De Gastroenterologia</i> , 2015, 52, 76-80.	0.3	5
146	European evidence based consensus on surgery for ulcerative colitis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 4-25.	0.6	285
147	Disease Duration Did Not Influence the Rates of Loss of Efficacy of the Anti-TNF Therapy in Latin American Crohn's Disease Patients. <i>Digestion</i> , 2015, 91, 158-163.	1.2	6
148	Direct Retrospective Comparison of Adalimumab and Infliximab in Preventing Early Postoperative Endoscopic Recurrence After Ileocaecal Resection for Crohn's Disease: Results from the MULTIPER Database. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 541-547.	0.6	27
149	Impact of anti-TNF agents in postoperative complications in Crohn's disease: a review. <i>Journal of Coloproctology</i> , 2015, 35, 128-136.	0.1	2
150	Recommendations on the use of biosimilars by the Brazilian Society of Rheumatology, Brazilian Society of Dermatology, Brazilian Federation of Gastroenterology and Brazilian Study Group on Inflammatory Bowel Disease—Focus on clinical evaluation of monoclonal antibodies and fusion proteins used in the treatment of autoimmune diseases. <i>Autoimmunity Reviews</i> , 2015, 14, 769-773.	2.5	21
151	Conventional Versus Biological Therapy for Prevention of Postoperative Endoscopic Recurrence in Patients With Crohn's Disease: an International, Multicenter, and Observational Study. <i>Intestinal Research</i> , 2015, 13, 259.	1.0	8
152	Postoperative topical analgesia of hemorrhoidectomy with poliresulen and cinchocaine: a prospective and controlled study. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 2014, 41, 92-98.	0.3	8
153	T300A GENETIC POLYMORPHISM: a susceptibility factor for Crohn's disease?. <i>Arquivos De Gastroenterologia</i> , 2014, 51, 97-101.	0.3	7
154	ADALIMUMAB FOR MAINTENANCE THERAPY FOR ONE YEAR IN CROHN'S DISEASE: results of a Latin American single-center observational study. <i>Arquivos De Gastroenterologia</i> , 2014, 51, 39-45.	0.3	7
155	Risk factors for postoperative endoscopic recurrence in Crohn's disease: a Brazilian observational study. <i>Journal of Coloproctology</i> , 2014, 34, 141-147.	0.1	0
156	The Impact of Preoperative Anti-TNF in Surgical and Infectious Complications of Abdominal Procedures for Crohn's Disease: Controversy Still Persists. <i>American Journal of Gastroenterology</i> , 2014, 109, 139.	0.2	6
157	Taylored prevention of postoperative endoscopic recurrence in Crohn's disease: new data for an old problem. <i>Journal of Coloproctology</i> , 2014, 34, 065-066.	0.1	0
158	Is there any relation between gastric bypass for morbid obesity and the development of Crohn's disease?. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 712-713.	0.6	17
159	P511 Does the location of an IBD centre impact the rates of early postoperative endoscopic recurrence after ileocecal resection in Crohn's disease? Results from the MULTIPER database. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S281.	0.6	2
160	PERIANAL COMPLETE REMISSION WITH COMBINED THERAPY (SETON PLACEMENT AND ANTI-TNF AGENTS) IN CROHN'S DISEASE: a Brazilian multicenter observational study. <i>Arquivos De Gastroenterologia</i> , 2014, 51, 284-289.	0.3	27
161	RESEARCH IN INFLAMMATORY BOWEL DISEASES IN LATIN AMERICA: a challenge ahead. <i>Arquivos De Gastroenterologia</i> , 2014, 51, 269-270.	0.3	4
162	Endoscopic Postoperative Recurrence Rates in Crohn's Disease in Korea: The Beginning of a New Approach?. <i>Intestinal Research</i> , 2014, 12, 258.	1.0	2

#	ARTICLE	IF	CITATIONS
163	Comparative analysis of adverse events between infliximab and adalimumab in Crohn's disease management: a Brazilian single-centre experience. <i>Journal of Coloproctology</i> , 2013, 33, 033-038.	0.1	1
164	Complications after intestinal resection in Crohn's disease: laparoscopic versus conventional approach. <i>Journal of Coloproctology</i> , 2013, 33, 139-144.	0.1	3
165	Is fecal calprotectin useful for monitoring endoscopic disease activity in patients with postoperative Crohn's disease?. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e712.	0.6	6
166	Sarcoidosis during therapy with adalimumab in a Crohn's disease patient: A paradoxical effect. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e599-e600.	0.6	11
167	Human fibrinogen and thrombin patch for extraluminal protection of intestinal anastomosis. <i>Journal of Coloproctology</i> , 2013, 33, 174-178.	0.1	2
168	Infliximab versus azathioprine to prevent postoperative recurrence in Crohn's disease: are all controversial issues defined?. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e698.	0.6	3
169	P-128â€fRisk Factors for Postoperative Endoscopic Recurrence in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, S74-S75.	0.9	0
170	P-129â€fSelf-injections and Adherence with Adalimumab Therapy in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, S75.	0.9	0
171	DECISION TREE CONSTRUCTION AND COST-EFFECTIVENESS ANALYSIS OF TREATMENT OF ULCERATIVE COLITIS WITH PENTASA®MESALAZINE 2 G SACHET. <i>Arquivos De Gastroenterologia</i> , 2013, 50, 297-303.	0.3	4
172	Burrill Bernard Crohn (1884-1983): o homem por trás da doença. <i>Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery</i> , 2013, 26, 253-255.	0.5	9
173	Biological Therapy for the Prevention and Treatment of Postoperative Endoscopic Recurrence in Crohn's Disease: Time for Acceptance?. <i>Intestinal Research</i> , 2013, 11, 256.	1.0	6
174	Combined Therapy With Surgery and Anti-TNF Therapy for Perianal Crohn's Disease: Seton Withdrawal Timing Data From a Brazilian Case Series. <i>Inflammatory Bowel Diseases</i> , 2012, 18, S59.	0.9	0
175	Sacrococcygeal hernia: a challenge for the coloproctologist. <i>Journal of Coloproctology</i> , 2012, 32, 416-421.	0.1	1
176	Appropriateness of colonoscopy indication for colorectal neoplasm detection in patients under 50 years old with hematochezia. <i>Journal of Coloproctology</i> , 2012, 32, 40-49.	0.1	2
177	Epidemiological profile of 175 patients with Crohn's disease submitted to biological therapy. <i>Journal of Coloproctology</i> , 2012, 32, 395-401.	0.1	7
178	Efeito do anti-TNF-Î± em implantes endometriais no peritônio de ratas. <i>Revista Do Colegio Brasileiro De Cirurgioes</i> , 2011, 38, 266-273.	0.3	6
179	Biological therapy does not increase post operative complications after major abdominal surgery in crohn's disease brazilian patients. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S43.	0.9	8
180	Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series. <i>Journal of Coloproctology</i> , 2011, 31, 233-240.	0.1	4

#	ARTICLE	IF	CITATIONS
181	A Broad Panel of Autoantibodies in Patients With Celiac Disease and Crohn's Disease. Journal of Clinical Gastroenterology, 2010, 44, 309-310.	1.1	2
182	Antibodies anti-Saccharomyces cerevisiae (ASCA) do not differentiate Crohn's disease from celiac disease. Arquivos De Gastroenterologia, 2010, 47, 242-245.	0.3	23
183	Análise das complicações tardias em operações anorretais: experiência de um serviço de referência em coloproctologia. Revista Brasileira De Coloproctologia, 2010, 30, 305-317.	0.2	3
184	Motor neuropathy with multiple conduction blocks associated with TNF-alpha antagonist. Arquivos De Neuro-Psiquiatria, 2010, 68, 452-454.	0.3	12
185	Reindução da remissão clínica com adalimumabe após interrupção do tratamento: uma alternativa no manejo da doença de Crohn. Revista Brasileira De Coloproctologia, 2010, 30, 135-140.	0.2	1
186	Análise de custos entre a raquianestesia e a anestesia venosa com propofol associada ao bloqueio perianal local em operações anorretais. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2009, 22, 137-142.	0.5	1
187	Análise de custo-minimização entre o Infliximabe (IFX) e o Adalimumabe (ADA) no tratamento da doença de Crohn (DC). Revista Brasileira De Coloproctologia, 2009, 29, 158-168.	0.2	5
188	Influência da técnica de anestesia no tempo de ocupação de sala cirúrgica nas operações anorretais. Revista Brasileira De Coloproctologia, 2008, 28, 227-233.	0.2	3